Hiroaki Itamochi1, Nao Oumi2, Tetsuro Oishi2, Tadahiro Shoji3, Hiroyuki Fujiwara4, Toru Sugiyama3, Mitsuaki Suzuki4, Junzo Kigawa5, Tasuku Harada2. 1. Department of Obstetrics and Gynecology, Tottori University School of Medicine, 36-1 Nishicho, Yonago, Tottori, 683-8504, Japan. itamochi@hotmail.com. 2. Department of Obstetrics and Gynecology, Tottori University School of Medicine, 36-1 Nishicho, Yonago, Tottori, 683-8504, Japan. 3. Department of Obstetrics and Gynecology, Iwate Medical University, 19-1 Uchimaru, Morioka, Iwate, 020-8505, Japan. 4. Department of Obstetrics and Gynecology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan. 5. Matsue City Hospital, 32-1 Noshira, Matsue, Shimane, 690-8509, Japan.
Abstract
BACKGROUND: Recent studies have shown that somatic mutations in the AT-rich interactive domain 1A (SWI-like) gene (ARID1A) are the most common genetic changes in clear cell carcinoma of the ovary (CCC). A gene mutation of ARID1A was found in approximately half of CCC cases, and led to absence of the encoded protein and inactivation of the putative tumor suppressor. Here, we investigated whether ARID1A could be a prognostic biomarker for this disease. METHODS: We analyzed the protein expression of ARID1A in CCC from 112 patients by immunohistochemical staining, and evaluated the association of these molecular parameters with clinical outcome. RESULTS: The loss of ARID1A expression was found in 39 % (44/112) of CCC, and was not associated with patient age, FIGO stage, and status of residual tumor. The 5-year survival rate for FIGO stage I or II patients with negative tumor expression of ARID1A was lower than those with positive tumor expression of ARID1A (74 % vs 91 %), but this difference was not observed in FIGO stage III or IV patients. Multivariable analysis revealed that ARID1A expression was an independent prognostic factor in FIGO stage I or II CCC patients. CONCLUSION: ARID1A may be a biomarker that is predictive of the outcome of FIGO stage I and II CCC.
BACKGROUND: Recent studies have shown that somatic mutations in the AT-rich interactive domain 1A (SWI-like) gene (ARID1A) are the most common genetic changes in clear cell carcinoma of the ovary (CCC). A gene mutation of ARID1A was found in approximately half of CCC cases, and led to absence of the encoded protein and inactivation of the putative tumor suppressor. Here, we investigated whether ARID1A could be a prognostic biomarker for this disease. METHODS: We analyzed the protein expression of ARID1A in CCC from 112 patients by immunohistochemical staining, and evaluated the association of these molecular parameters with clinical outcome. RESULTS: The loss of ARID1A expression was found in 39 % (44/112) of CCC, and was not associated with patient age, FIGO stage, and status of residual tumor. The 5-year survival rate for FIGO stage I or II patients with negative tumor expression of ARID1A was lower than those with positive tumor expression of ARID1A (74 % vs 91 %), but this difference was not observed in FIGO stage III or IV patients. Multivariable analysis revealed that ARID1A expression was an independent prognostic factor in FIGO stage I or II CCC patients. CONCLUSION:ARID1A may be a biomarker that is predictive of the outcome of FIGO stage I and II CCC.
Authors: Zsuzsanna Lichner; Andreas Scorilas; Nicole M A White; Andrew H Girgis; Lora Rotstein; Kimberly C Wiegand; Ashraf Latif; Christina Chow; David Huntsman; George M Yousef Journal: Am J Pathol Date: 2013-02-12 Impact factor: 4.307
Authors: William J Lowery; Joellen M Schildkraut; Liudmila Akushevich; Rex Bentley; Jeffrey R Marks; David Huntsman; Andrew Berchuck Journal: Int J Gynecol Cancer Date: 2012-01 Impact factor: 3.437
Authors: Melissa K McConechy; Jiarui Ding; Janine Senz; Winnie Yang; Nataliya Melnyk; Alicia A Tone; Leah M Prentice; Kimberly C Wiegand; Jessica N McAlpine; Sohrab P Shah; Cheng-Han Lee; Paul J Goodfellow; C Blake Gilks; David G Huntsman Journal: Mod Pathol Date: 2013-06-14 Impact factor: 7.842
Authors: Kimberly C Wiegand; Bryan T Hennessy; Samuel Leung; Yemin Wang; Zhenlin Ju; Mollianne McGahren; Steve E Kalloger; Sarah Finlayson; Katherine Stemke-Hale; Yiling Lu; Fan Zhang; Michael S Anglesio; Blake Gilks; Gordon B Mills; David G Huntsman; Mark S Carey Journal: BMC Cancer Date: 2014-02-22 Impact factor: 4.430
Authors: Corey M Gill; Joshua Loewenstern; John W Rutland; Hanane Arib; Margaret Pain; Melissa Umphlett; Yayoi Kinoshita; Russell B McBride; Joshua Bederson; Michael Donovan; Robert Sebra; Mary Fowkes; Raj K Shrivastava Journal: J Cancer Res Clin Oncol Date: 2021-03-14 Impact factor: 4.553
Authors: Valentino Clemente; Asumi Hoshino; Mihir Shetty; Andrew Nelson; Britt K Erickson; Ruth Baker; Nathan Rubin; Mahmoud Khalifa; S John Weroha; Emil Lou; Martina Bazzaro Journal: Cancer Res Commun Date: 2022-08-10
Authors: Karolin Heinze; Tayyebeh M Nazeran; Sandra Lee; Pauline Krämer; Evan S Cairns; Derek S Chiu; Samuel Cy Leung; Eun Young Kang; Nicola S Meagher; Catherine J Kennedy; Jessica Boros; Friedrich Kommoss; Hans-Walter Vollert; Florian Heitz; Andreas du Bois; Philipp Harter; Marcel Grube; Bernhard Kraemer; Annette Staebler; Felix Kf Kommoss; Sabine Heublein; Hans-Peter Sinn; Naveena Singh; Angela Laslavic; Esther Elishaev; Alex Olawaiye; Kirsten Moysich; Francesmary Modugno; Raghwa Sharma; Alison H Brand; Paul R Harnett; Anna DeFazio; Renée T Fortner; Jan Lubinski; Marcin Lener; Aleksandra Tołoczko-Grabarek; Cezary Cybulski; Helena Gronwald; Jacek Gronwald; Penny Coulson; Mona A El-Bahrawy; Michael E Jones; Minouk J Schoemaker; Anthony J Swerdlow; Kylie L Gorringe; Ian Campbell; Linda Cook; Simon A Gayther; Michael E Carney; Yurii B Shvetsov; Brenda Y Hernandez; Lynne R Wilkens; Marc T Goodman; Constantina Mateoiu; Anna Linder; Karin Sundfeldt; Linda E Kelemen; Aleksandra Gentry-Maharaj; Martin Widschwendter; Usha Menon; Kelly L Bolton; Jennifer Alsop; Mitul Shah; Mercedes Jimenez-Linan; Paul Dp Pharoah; James D Brenton; Kara L Cushing-Haugen; Holly R Harris; Jennifer A Doherty; Blake Gilks; Prafull Ghatage; David G Huntsman; Gregg S Nelson; Anna V Tinker; Cheng-Han Lee; Ellen L Goode; Brad H Nelson; Susan J Ramus; Stefan Kommoss; Aline Talhouk; Martin Köbel; Michael S Anglesio Journal: J Pathol Date: 2022-02-07 Impact factor: 9.883
Authors: Hyun Deuk Cho; Jong Eun Lee; Hae Yoen Jung; Mee-Hye Oh; Ji-Hye Lee; Si-Hyong Jang; Kyung-Ju Kim; Sun Wook Han; Sung Yong Kim; Han Jo Kim; Sang Byung Bae; Hyun Ju Lee Journal: J Breast Cancer Date: 2015-12-23 Impact factor: 3.588